Volume 3.40 | Oct 9

Pancreatic Cell News 3.40 October 9, 2012
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs 
Cell Therapy News on Facebook  Pancreatic Cell News on Twitter
TOP STORY
Treatment of Autoimmune Diabetes in NOD Mice by Toll-Like Receptor 2 Tolerance in Conjunction with Dipeptidyl Peptidase 4 Inhibition
Scientists investigated whether a combination of dipeptidyl peptidase 4 inhibition, with beneficial effects on beta cell mass, and toll-like receptor 2 tolerisation, protecting beta cells from autoimmune destruction, could treat a model of established type 1 diabetes. [Diabetologia] Abstract


Register for Training Course: Air-Liquid Interface Culture of Primary Human Bronchial Epithelial Cells
PUBLICATIONS (Ranked by impact factor of the journal)

DIABETES

Ciliary Neurotrophic Factor Protects Mice Against Streptozotocin-Induced Type 1 Diabetes through SOCS3: The Role of STAT1/STAT3 Ratio in β-Cell Death
Investigators assessed whether ciliary neurotrophic factor protects mice against streptozotocin-induced diabetes and the mechanism for this protection. [J Biol Chem] Abstract | Full Article

Increased Expression of the Glucose-Responsive Gene, RCAN1, Causes Hypoinsulinemia, β-Cell Dysfunction, and Diabetes
Researchers investigated the presence of regulator of calcineurin 1 (RCAN1) in β-cells and identified its role in β-cell function. RCAN1 is expressed in mouse islets and in the cytosol of pancreatic β-cells. [Endocrinology] Abstract

Overexpression of PPARα in Pancreatic β-Cells Improves Glucose Tolerance in Diet-Induced Obese Mice
Scientists showed that overexpression of peroxisome proliferator-activated receptor alpha (PPARα) in pancreatic β-cells in vivo preserves β-cell function in obesity, and this improves glucose tolerance by preserving insulin secretion compared to control mice with diet-induced obesity. [Exp Physiol] Abstract

Treg Cells in Pancreatic Lymph Nodes: The Possible Role in Diabetogenesis and β Cell Regeneration in a Type 1 Diabetes Model
The authors investigated the role of T regulatory (Treg) cells in the mechanisms mediating the restoration of euglycemia in the antea-diabetic non-obese diabetic (NOD) model. The data demonstrated that the numbers of Treg cells were decreased in unmanipulated NOD mice, with the most profound deficiency detected in the pancreatic lymph nodes. [Cell Mol Immunol] Abstract | Press Release

A Compound (DW1182v) Protecting High Glucose/Palmitate-Induced Glucolipotoxicity to INS-1 Beta Cells Preserves Islet Integrity and Improves Hyperglycemia in Obese db/db Mouse
Researchers screened a representative library for prevention of high glucose/palmitate (HG/PA)-induced viability reduction of INS-1 beta cells and identified a new small molecule (DW1182v) with a function to protect HG/PA-induced glucolipotoxicity. [Eur J Pharmacol] Abstract

PANCREATIC CANCER

Activation of Nuclear Factor-κB in Acinar Cells Increases the Severity of Pancreatitis in Mice
To model constitutive activation of nuclear factor (NF)-κB, researchers expressed a transgene that encodes its p65 subunit or the inhibitor of κB kinase 2 (IKK2) in pancreatic acinar cells of mice. They analyzed effects on pancreatic tissues and levels of NF-κB target genes in these mice and compared them to mice that did not express transgenic p65 or IKK2. [Gastroenterology] Abstract

Paclitaxel and CYC3, an Aurora Kinase A Inhibitor, Synergize in Pancreatic Cancer Cells but not Bone Marrow Precursor Cells
A novel AK-A inhibitor, CYC3 was investigated in pancreatic cancer cell lines, in combination with paclitaxel. [Br J Cancer] Full Article

Involvement of Oncogenic K-Ras on Cell Migration Stimulated by Lysophosphatidic Acid Receptor-2 in Pancreatic Cancer Cells
To evaluate the function of lysophosphatidic acid receptor-2 on motile and invasive activities of pancreatic cancer cells, the authors generated Lpar2 knockdown cells from hamster pancreatic cancer cells and measured their cell migration ability. [Exp Cell Res] Abstract

Mesothelin Regulates Growth and Apoptosis in Pancreatic Cancer Cells through p53-Dependent and -Independent Signal Pathway
Scientists evaluated the effects of mesothelin on proliferation and apoptosis in pancreatic cancer cells with different p53 status and explored its signal pathway. [J Exp Clin Cancer Res] Abstract | Full Article

Pancreatic Cancer Cells Surviving Gemcitabine Treatment Express Markers of Stem Cell Differentiation and Epithelial-Mesenchymal Transition
Researchers investigated the expression of stem cell genes and markers of epithelial-mesenchymal transition in pancreatic cancer cells that survived high concentrations of gemcitabine treatment. [Int J Oncol] Abstract

Do Your Colleagues Know What They Are Missing? Share This Newsletter Now.

REVIEWS

Aldosterone and Angiotensin: Role in Diabetes and Cardiovascular Diseases
This review summarizes the role of renin-angiotensin aldosterone system (RAAS). The local RAAS operates in an autocrine, paracrine and/or intracrine manner and exhibits multiple physiological effects at the cellular level. In addition to local RAAS, there exists a complete pancreatic RAAS which has multi-facet role in diabetes and cardiovascular diseases. [Eur J Pharmacol] Abstract

SCIENCE NEWS

Phase IIb Data Showed Merck’s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes
Merck announced phase IIb data for MK-3102, the company’s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes. MK-3102 significantly lowered blood sugar in this 12-week study compared with placebo, with an incidence of symptomatic hypoglycemia that was similar to placebo, in patients with type 2 diabetes. [Press release from Merck Sharp & Dohme Corp. discussing data presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin]
Press Release


Lilly and Boehringer Ingelheim Present Health Outcomes Data for Investigational Novel Basal Insulin Analogue

Eli Lilly and Company and Boehringer Ingelheim announced patient-reported health outcomes data from a phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes. [Press release from Boehringer Ingelheim GmbH discussing data to be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin] Press Release

INDUSTRY NEWS

The Nobel Prize in Physiology or Medicine 2012: Sir John B. Gurdon, Shinya Yamanaka
Nobel Assembly at Karolinska Institutet has decided to award The Nobel Prize in Physiology or Medicine 2012 jointly to John B. Gurdon and Shinya Yamanaka for the discovery that mature cells can be reprogrammed to become pluripotent. [Nobel Media AB] Press Release

NIH Awards $9.5 Million Grant to Joslin Diabetes Center to Support Diabetes Research
Joslin Diabetes Center has been awarded a $9.5 million, multi-year Diabetes Research Center grant from the National Institutes of Diabetes, Digestive and Kidney Disorders of the National Institute of Health (NIH). [Joslin Diabetes Center] Press Release

MorphoSys’s Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase Ib/II Clinical Trial in Pancreatic Cancer

MorphoSys AG announced that its collaboration partner OncoMed Pharmaceuticals has advanced the HuCAL antibody OMP-59R5 into the next stage of clinical development. OMP-59R5 is now being evaluated in a phase Ib/II trial in the US in first-line advanced pancreatic cancer patients. [MorphoSys AG] Press Release

POLICY NEWS

Australian Panel Calls for Major Changes in Nation’s Biomedical Research
An Australian advisory panel is suggesting sweeping changes to the nation’s biomedical research programs in order to better link science to health care – along with a hefty spending boost. But the recommendations come as the Australian government is reportedly considering a freeze on research grants as part of austerity plans. [Strategic Review of Health and Medical Research in Australia, Australia] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

National Health Service (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW Keystone Symposia: Immunopathology of Type 1 Diabetes
April 4-9, 2013
Whistler, Canada


Visit our events page to see a complete list of events in the pancreatic cell community.

JOB OPPORTUNITIES

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Postdoctoral Position – Beta Cell Biology and Translational Research (University of California, Los Angeles)

Postdoctoral Position – Diabetes Research (Monash University)

Postdoctoral Position – Type 1 Diabetes Research (Sanford Health/University of South Dakota)

Postdoctoral Position – Pancreatic Beta Cell Biology (CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences)

Postdoctoral Position – Signaling Pathways Pancreatic Beta-Cells (CNRS – Centre National de la Recherche Scientifique)

Postdoctoral Position – Cholesterol Homeostasis in Pancreatic Islets (Centre of Molecular Medicine and Therapeutics)

Postdoctoral Position – Beta Cell Biology (Umea Center for Molecular Medicine)

Recruit Top Talent
: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Pancreatic Cell News: Archives | Events | Contact Us